MRKR Stock Analysis: Buy, Sell, or Hold?
MRKR - Marker Therapeutics, Inc. Common Stock
$1.52
0.02 (1.33%)
▲
5d:
+32.17%
30d:
+24.59%
90d:
+4.83%
WAIT
LOW Confidence
Analysis Updated: Aug 25, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When MRKR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: MRKR is 15.2% above its trading range ($1.32). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: MRKR is 15.2% above its trading range ($1.32). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: MRKR is currently trading at $1.52, which is considered extended relative to its 30-day fair value range of $1.11 to $1.32.
Technical Outlook: Technically, MRKR is in a downtrend. Immediate support is located at $1.09, while resistance sits at $1.60.
Market Sentiment: MRKR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.87 (+417.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRKR is in a downtrend. Immediate support is located at $1.09, while resistance sits at $1.60.
Market Sentiment: MRKR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.87 (+417.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.11 -
$1.32
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+15.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 417.5% below Wall St target ($7.87)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.11 -
$1.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$1.60
Current Trend
Downtrend
Technical data as of
Aug 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.87
Wall Street Target
$7.87
(+417.5%)
Revenue Growth (YoY)
-51.0%
Profit Margin
-245.5%
Share & Embed Analysis
Last updated: August 25, 2026 11:51 PM ET
Data refreshes hourly during market hours. Next update: 12:51 AM
Data refreshes hourly during market hours. Next update: 12:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRKR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 41 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 48 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 33 SELL |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 39 SELL |
